Importantly, no difference in immune infiltration was observed between NLRC4hiIL-18hi and NLRC4hiIL-18lo populations, and the loss of NLRC4 tumor expression within the IL-18lo population reduced mild infiltration to low levels of both CD3+ and CD8+ T cells in tumors (~20% in frequency, respectively). The gene discussed is NLRC4; the disease is neoplasm.